QR Group Explains the Role of the Brazilian Registration Holder in Medical Device Regulation

Medical device registration process with ANVISA.

How Foreign Manufacturers Can Market Medical Devices in Brazil For foreign medical device manufacturers to distribute their products in Brazil without having a licensed company in the country, it is necessary to appoint a Brazilian Registration Holder (BRH). This regulatory representative acts as the link between the company and the National Health Surveillance Agency (ANVISA), […]

Medical Device and In Vitro Diagnostic Registration: The Complete Guide for Foreign Manufacturers in Brazil

Registration of medical devices with ANVISA with consultancy from QR Group.

Understand how ANVISA regulations affect the registration of medical devices and in vitro diagnostics and how QR Group can help with compliance. Brazil, the largest medical device market in Latin America, offers great growth opportunities for international manufacturers. However, the regulatory process for medical devices and in vitro diagnostic products requires detailed attention to ANVISA […]

QR Group Explains ANVISA’s Good Manufacturing Practices Inspection for Medical Devices

ANVISA GMP inspection to ensure compliance of medical devices in Brazil.

Understand how GMP inspection impacts the registration of medical devices and how QR Group facilitates the compliance process. ANVISA requires that a Good Manufacturing Practices (GMP) Inspection be carried out at the facilities of manufacturers of risk class III and IV medical devices, whether national or international, as part of the process for product registration. […]

How Avisalegis Can Make It Easier to Follow ANVISA Regulations

Avisalegis ANVISA: Tool for regulatory monitoring of medical devices.

What is Avisalegis and How Does It Impact the Healthcare Industry? The National Health Surveillance Agency (ANVISA) recently launched Avisalegis, an innovative service that allows you to receive alerts about new regulatory publications. With this tool, medical device manufacturers, pharmaceutical companies, and other regulated industries can quickly keep up with any updates that impact their […]

QR Group Explains RDC 947/2024: The End of Paper Protocol at ANVISA

ANVISA digital protocol: new regulations for electronic submission of documents.

Understand how the digitalization of ANVISA’s protocol impacts regulatory processes and how QR Group can help your company As of March 13, 2025, the National Health Surveillance Agency (ANVISA) will implement a 100% digital protocol for receiving documents, as established by RDC 947/2024. With this change, the submission of paper documents will no longer be […]

RDC 954/2024: Updates to the Simplified Drug Registration Procedure

Experts discuss RDC 954/2024 and its impact on drug registration in Brazil.

Key Changes and Impacts for Drug Manufacturers The recent update of RDC 954/2024 brought significant changes to the simplified procedure for registering medicines in Brazil. In an exclusive event held by ANVISA on March 13, experts discussed the main guidelines and their impacts on the pharmaceutical sector. QR Group has closely followed the news to […]

QR Group Explains Anvisa’s Approval of 124 Drugs for Rare Diseases

Anvisa approval of drugs for rare diseases with support from QR Group

Advanced Regulation Boosts Treatments for Rare Diseases Anvisa has played a key role in the approval of drugs aimed at rare diseases, achieving a total of 124 approvals in the last eight years. This advance reflects the agency’s commitment to optimizing regulatory processes, ensuring more therapeutic options for patients facing diseases that are often chronic, […]

Anvisa Resumes Monitoring of Medical Device Prices: What Does This Mean for the Sector?

ANVISA update on monitoring medical device prices.

Transparency and Regulation: QR Group Explains the Resumption of Data Publication Anvisa has resumed the publication of medical device price monitoring data on its Business Intelligence (BI) dashboards. This activity, previously suspended due to the Agency’s internal restructuring, once again offers crucial information for the health sector. With this resumption, companies in the segment have […]